BRAF-mutated erdheim-chester disease: Profound response to vemurafenib visualized with serial multimodality imaging

Javaughn Corey R. Gray, Jongho Kim, Michael Digianvittorio, Nancy K. Feeley, Paul J. Scheel, Stanley S. Siegelman, Elliot K. Fishman, Steven P. Rowe

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Erdheim-Chester disease (ECD) is an extremely rare and aggressive non-Langerhans histiocytic disorder. ECD typically presents with bone pain in middle-aged adults, although some patients present with multisystem disease involving the skeleton, central nervous system, cardiovascular system, lungs, and other disease sites. The etiology of ECD is currently unknown, but it is thought to be a reactive or neoplastic disorder. Recently, mutation of the BRAF gene has been found in .50% of ECD cases, and this gene has become a therapeutic target for patients with ECD. Vemurafenib, a BRAF inhibitor, has been approved by the FDA for treatment of ECD. This report presents an elderly male patient with an aggressive phenotype of ECD and highlights the utility of multimodality imaging in monitoring the clinical course and disease response to treatment with vemurafenib.

Original languageEnglish
Pages (from-to)650-655
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume18
Issue number6
DOIs
StatePublished - Jun 2020

Fingerprint

Dive into the research topics of 'BRAF-mutated erdheim-chester disease: Profound response to vemurafenib visualized with serial multimodality imaging'. Together they form a unique fingerprint.

Cite this